Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is ICER Too NICE? A Comparison Of Drug Assessments Programs

Executive Summary

Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.

Advertisement

Related Content

Psoriasis Drug Valuation By ICER May Undercut Routine Step Therapy
NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut
ICER Report Questions Cost-Effectiveness Of PD-1 Drugs In Lung Cancer
NICE Reassessing Old CDF Drugs On Value-For-Money Basis – Some Fail
ICER Eyes QALY Ratios, Budget Impacts In Methods Review
Intercept's Pricing Of Ocaliva Anticipates Outcomes Data
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza
Hepatitis C Pricing: Insurers' Cost Benchmarks Would Yield Optimal Price Of $42,000 – Report

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel